FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation at The Cell & Gene Meeting On The Mediterranean in Rome from April 15-17, 2025. The company's Chief Scientific Officer, Dr. Hamid Khoja, will present on their innovative fibroblast cell-based therapeutic approach for chronic diseases.
The presentation, titled 'Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases,' will take place on Wednesday, April 16 at 9:00 AM CEST at the Salone dei Cavalieri.
FibroBiologics specializes in developing treatments using fibroblast cells and fibroblast-derived materials, with a significant intellectual property portfolio of 240+ US and international patents. Their research spans multiple therapeutic areas including:
- Wound healing
- Multiple sclerosis
- Disc degeneration
- Psoriasis
- Orthopedics
- Human longevity
- Cancer
FibroBiologics (Nasdaq: FBLG), un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione al The Cell & Gene Meeting On The Mediterranean a Roma dal 15 al 17 aprile 2025. Il Chief Scientific Officer dell'azienda, Dr. Hamid Khoja, presenterà il loro approccio terapeutico innovativo basato su cellule fibroblastiche per le malattie croniche.
La presentazione, intitolata 'Ripristinare l'omeostasi del sistema immunitario utilizzando una terapia basata su cellule fibroblastiche mirata a tre malattie mediate da infiammazione cronica,' si terrà mercoledì 16 aprile alle 9:00 CEST presso il Salone dei Cavalieri.
FibroBiologics si specializza nello sviluppo di trattamenti utilizzando cellule fibroblastiche e materiali derivati da fibroblasti, con un significativo portafoglio di proprietà intellettuale di oltre 240 brevetti statunitensi e internazionali. La loro ricerca copre molteplici aree terapeutiche tra cui:
- Guarigione delle ferite
- Sclerosi multipla
- Degenerazione del disco
- Psoriasi
- Ortopedia
- Longevità umana
- Cancro
FibroBiologics (Nasdaq: FBLG), una empresa de biotecnología en etapa clínica, anunció su participación en The Cell & Gene Meeting On The Mediterranean en Roma del 15 al 17 de abril de 2025. El Director Científico de la empresa, Dr. Hamid Khoja, presentará su enfoque terapéutico innovador basado en células fibroblásticas para enfermedades crónicas.
La presentación, titulada 'Restaurando la homeostasis del sistema inmunológico utilizando una terapia basada en células fibroblásticas dirigida a tres enfermedades mediadas por inflamación crónica,' tendrá lugar el miércoles 16 de abril a las 9:00 AM CEST en el Salone dei Cavalieri.
FibroBiologics se especializa en el desarrollo de tratamientos utilizando células fibroblásticas y materiales derivados de fibroblastos, con un importante portafolio de propiedad intelectual de más de 240 patentes estadounidenses e internacionales. Su investigación abarca múltiples áreas terapéuticas, incluyendo:
- Curación de heridas
- Esclerosis múltiple
- Degeneración de disco
- Psoriasis
- Ortopedia
- Longevidad humana
- Cáncer
FibroBiologics (Nasdaq: FBLG), 임상 단계의 생명공학 회사,는 2025년 4월 15일부터 17일까지 로마에서 열리는 The Cell & Gene Meeting On The Mediterranean에 참여한다고 발표했습니다. 회사의 최고 과학 책임자 Dr. Hamid Khoja는 만성 질환을 위한 혁신적인 섬유아세포 기반 치료 접근법을 발표할 것입니다.
'만성 염증 매개 질환 세 가지를 겨냥한 섬유아세포 기반 치료를 통한 면역 체계 항상성 회복'이라는 제목의 발표는 4월 16일 수요일 오전 9시 CEST에 Salone dei Cavalieri에서 진행됩니다.
FibroBiologics는 섬유아세포 및 섬유아세포 유래 물질을 사용한 치료 개발을 전문으로 하며, 240개 이상의 미국 및 국제 특허로 구성된 중요한 지적 재산 포트폴리오를 보유하고 있습니다. 그들의 연구는 다음과 같은 여러 치료 분야를 포함합니다:
- 상처 치유
- 다발성 경화증
- 디스크 퇴행
- 건선
- 정형외과
- 인간의 장수
- 암
FibroBiologics (Nasdaq: FBLG), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à The Cell & Gene Meeting On The Mediterranean à Rome du 15 au 17 avril 2025. Le Directeur Scientifique de l'entreprise, Dr. Hamid Khoja, présentera leur approche thérapeutique innovante basée sur des cellules fibroblastiques pour les maladies chroniques.
La présentation, intitulée 'Restaurer l'homéostasie du système immunitaire en utilisant une thérapie basée sur des cellules fibroblastiques ciblant trois maladies médiées par l'inflammation chronique,' aura lieu le mercredi 16 avril à 9h00 CEST au Salone dei Cavalieri.
FibroBiologics se spécialise dans le développement de traitements utilisant des cellules fibroblastiques et des matériaux dérivés de fibroblastes, avec un portefeuille de propriété intellectuelle significatif de plus de 240 brevets américains et internationaux. Leur recherche couvre plusieurs domaines thérapeutiques, y compris :
- Cicatrisation des plaies
- Sclérose en plaques
- Dégénérescence discale
- Psoriasis
- Orthopédie
- Longévité humaine
- Cancer
FibroBiologics (Nasdaq: FBLG), ein biopharmazeutisches Unternehmen in der klinischen Phase, gab seine Teilnahme an der The Cell & Gene Meeting On The Mediterranean in Rom vom 15. bis 17. April 2025 bekannt. Der Chief Scientific Officer des Unternehmens, Dr. Hamid Khoja, wird über ihren innovativen therapeutischen Ansatz auf Basis von Fibroblasten für chronische Krankheiten referieren.
Die Präsentation mit dem Titel 'Wiederherstellung der Homöostase des Immunsystems durch eine auf Fibroblasten basierende Therapie zur gezielten Behandlung dreier chronischer Entzündungserkrankungen' findet am Mittwoch, den 16. April um 9:00 Uhr CEST im Salone dei Cavalieri statt.
FibroBiologics ist auf die Entwicklung von Behandlungen mit Fibroblasten und aus Fibroblasten abgeleiteten Materialien spezialisiert und verfügt über ein bedeutendes Portfolio an geistigem Eigentum mit über 240 US- und internationalen Patenten. Ihre Forschung umfasst mehrere therapeutische Bereiche, darunter:
- Wundheilung
- Multiple Sklerose
- Diskdegeneration
- Psoriasis
- Orthopädie
- Menschliche Langlebigkeit
- Krebs
- None.
- None.
HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic diseases at The Cell & Gene Meeting On The Mediterranean (Med) in Rome, Italy, from April 15-17, 2025. The Cell & Gene Meeting on the Med is the leading conference bringing together the Advanced Therapy Medicinal Products community from Europe and beyond.
Details of the conference and presentations are as follows:
The Cell & Gene Meeting On The Med
Presentation Title: Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases
Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics
Location: Salone dei Cavalieri, Section 2
Date and Time: Wednesday, April 16 at 9:00 AM CEST
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 240+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What will FibroBiologics (FBLG) present at the Cell & Gene Meeting on the Mediterranean 2025?
How many patents does FibroBiologics (FBLG) currently hold?
What medical conditions is FibroBiologics (FBLG) targeting with their fibroblast technology?
What is FibroBiologics' (FBLG) main therapeutic approach?
Where is FibroBiologics (FBLG) headquartered?
